Casokefamide
 | |
| Clinical data | |
|---|---|
| Other names | L-tyrosyl-D-alanyl-L-phenylalanyl-D-alanyl-L-tyrosinamide |
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C33H40N6O7 |
| Molar mass | 632.718 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Casokefamide (INN), also known as β-casomorphin 4027 (β-CM-4027) and [D-Ala2,4,Tyr5]-β-casomorphin-5-amide, is a peripherally-specific, synthetic opioid pentapeptide with the amino acid sequence Tyr-D-Ala-Phe-D-Ala-Tyr-NH2.[1] Derived from the β-casomorphin sequence, it was designed with the intention of improving resistance to digestive enzymes so that it could be used as an antidiarrheal medicine.[1][2] Unlike other casomorphins, which are generally selective μ-opioid receptor agonists, casokefamide binds to both the μ- and δ-opioid receptors.[1] In a clinical study, casokefamide was found to be effective via the oral route for the treatment of chronic diarrhea, and did not produce any side effects.[2] However, further clinical development was not pursued and it was never marketed.
See also
References
- 1 2 3 Brantl V, Picone D, Amodeo P, Temussi PA (March 1993). "Solution structure of casokefamide". Biochemical and Biophysical Research Communications. 191 (3): 853–9. doi:10.1006/bbrc.1993.1295. PMID 8466524.
- 1 2 Schulte-Frohlinde E, Reindl W, Bierling D, et al. (March 2000). "Effects of oral casokefamide on plasma levels, tolerance, and intestinal transit in man". Peptides. 21 (3): 439–42. doi:10.1016/S0196-9781(00)00166-2. PMID 10793229. S2CID 44670226.